JP2002542256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542256A5 JP2002542256A5 JP2000612324A JP2000612324A JP2002542256A5 JP 2002542256 A5 JP2002542256 A5 JP 2002542256A5 JP 2000612324 A JP2000612324 A JP 2000612324A JP 2000612324 A JP2000612324 A JP 2000612324A JP 2002542256 A5 JP2002542256 A5 JP 2002542256A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutically acceptable
- acceptable salt
- amino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 34
- 150000003839 salts Chemical class 0.000 description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- YLZIMEJTDZWVJG-UHFFFAOYSA-N 2-heptylundecanoic acid Chemical compound CCCCCCCCCC(C(O)=O)CCCCCCC YLZIMEJTDZWVJG-UHFFFAOYSA-N 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 0 *N(CC[C@]1c(cc2)ccc2O)[C@@]1C(NC(CSSC[C@@](C(O)=O)NC(C1(CCCC1)CCN1)=O)C1=O)=O Chemical compound *N(CC[C@]1c(cc2)ccc2O)[C@@]1C(NC(CSSC[C@@](C(O)=O)NC(C1(CCCC1)CCN1)=O)C1=O)=O 0.000 description 4
- -1 2,2-dimethyl-1-oxopropyl Chemical group 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- XKNFNBFQZMTNPT-UHFFFAOYSA-N tert-butyl 2-heptylundecanoate Chemical compound CCCCCCCCCC(C(=O)OC(C)(C)C)CCCCCCC XKNFNBFQZMTNPT-UHFFFAOYSA-N 0.000 description 2
- DLMYFMLKORXJPO-UHFFFAOYSA-N 2-amino-3-[(triphenylmethyl)thio]propanoic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SCC(N)C(O)=O)C1=CC=CC=C1 DLMYFMLKORXJPO-UHFFFAOYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DPGZYOAHHNINRG-UHFFFAOYSA-N O=C1C(C2(CCC1)CNC(CSSCCCNCC2)C(=O)O)=O Chemical compound O=C1C(C2(CCC1)CNC(CSSCCCNCC2)C(=O)O)=O DPGZYOAHHNINRG-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13021599P | 1999-04-20 | 1999-04-20 | |
| US60/130,215 | 1999-04-20 | ||
| PCT/EP2000/003459 WO2000063234A2 (en) | 1999-04-20 | 2000-04-17 | Pyrrolidincarbonylamino cyclic disulfides as vcam-vla4 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002542256A JP2002542256A (ja) | 2002-12-10 |
| JP2002542256A5 true JP2002542256A5 (enExample) | 2007-06-14 |
Family
ID=22443611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000612324A Pending JP2002542256A (ja) | 1999-04-20 | 2000-04-17 | ピロリジンカルボニルアミノ環状ジスルフィド類 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6265572B1 (enExample) |
| EP (1) | EP1171452B1 (enExample) |
| JP (1) | JP2002542256A (enExample) |
| KR (1) | KR100636481B1 (enExample) |
| CN (1) | CN1167710C (enExample) |
| AR (1) | AR023546A1 (enExample) |
| AT (1) | ATE337331T1 (enExample) |
| AU (1) | AU769294B2 (enExample) |
| BR (1) | BR0009838A (enExample) |
| CA (1) | CA2370259A1 (enExample) |
| DE (1) | DE60030266T2 (enExample) |
| ES (1) | ES2269141T3 (enExample) |
| TR (1) | TR200103004T2 (enExample) |
| WO (1) | WO2000063234A2 (enExample) |
| ZA (1) | ZA200108018B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6939855B2 (en) * | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
| US20090043126A1 (en) * | 2005-02-28 | 2009-02-12 | Jordi Bosch I Llado | Process and Methods for the Preparation of Gabapentin and Its Intermediates |
| EP2510941A3 (en) | 2007-02-20 | 2013-01-23 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| BRPI0911652A2 (pt) | 2008-04-11 | 2015-08-04 | Merrimack Pharmaceuticals Inc | Ligantes de albumina sérica humana e seus conjugados |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| MX2014004025A (es) | 2011-10-17 | 2014-08-01 | Univ Muenster Wilhelms | Metodos de valoracion de riesgo de lmp y aparatos relacionados. |
| WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
| CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
-
2000
- 2000-04-14 US US09/548,992 patent/US6265572B1/en not_active Expired - Fee Related
- 2000-04-17 JP JP2000612324A patent/JP2002542256A/ja active Pending
- 2000-04-17 WO PCT/EP2000/003459 patent/WO2000063234A2/en not_active Ceased
- 2000-04-17 ES ES00929365T patent/ES2269141T3/es not_active Expired - Lifetime
- 2000-04-17 TR TR2001/03004T patent/TR200103004T2/xx unknown
- 2000-04-17 KR KR1020017013304A patent/KR100636481B1/ko not_active Expired - Fee Related
- 2000-04-17 CA CA002370259A patent/CA2370259A1/en not_active Abandoned
- 2000-04-17 DE DE60030266T patent/DE60030266T2/de not_active Expired - Fee Related
- 2000-04-17 BR BR0009838-8A patent/BR0009838A/pt not_active IP Right Cessation
- 2000-04-17 AT AT00929365T patent/ATE337331T1/de not_active IP Right Cessation
- 2000-04-17 EP EP00929365A patent/EP1171452B1/en not_active Expired - Lifetime
- 2000-04-17 AU AU47482/00A patent/AU769294B2/en not_active Ceased
- 2000-04-17 CN CNB008064601A patent/CN1167710C/zh not_active Expired - Fee Related
- 2000-04-19 AR ARP000101825A patent/AR023546A1/es active IP Right Grant
-
2001
- 2001-09-28 ZA ZA200108018A patent/ZA200108018B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022553994A5 (enExample) | ||
| US11021513B2 (en) | Peptidomimetics for the treatment of norovirus infection | |
| CN105164117B (zh) | 二肽和三肽环氧酮蛋白酶抑制剂 | |
| TW202233204A (zh) | 用於治療病毒感染之化合物及方法 | |
| TWI316942B (en) | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | |
| KR20220026538A (ko) | 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체 | |
| JPH09500120A (ja) | 環式ヒドラジン化合物 | |
| JP2003506354A5 (enExample) | ||
| TW200936131A (en) | Macrocyclic serine protease inhibitors | |
| JP2006182786A5 (enExample) | ||
| JP2013521295A (ja) | イムノプロテアソーム阻害のための化合物 | |
| JP2009507909A5 (enExample) | ||
| JP2008545793A5 (enExample) | ||
| JP2009500423A5 (enExample) | ||
| US20240277795A1 (en) | Inhibitors of cysteine proteases and methods of use thereof | |
| JP2015524394A (ja) | ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ | |
| US20180369209A1 (en) | Methods of treating pulmonary diseases and disorders | |
| JP2011523952A (ja) | シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用 | |
| JP2023510332A5 (enExample) | ||
| CN1282336A (zh) | 半海盘灵类似物 | |
| JP2004529172A5 (enExample) | ||
| MXPA06013221A (es) | Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros. | |
| JP7796311B2 (ja) | 脂質および組成物 | |
| JP2025515833A5 (enExample) | ||
| JP2006514956A5 (enExample) |